Share this video  

ESMO 2020 | QuEST1 clinical trial updates

Jason Redman, MD, National Cancer Institute, Bethesda, MD, gives an overview of his presentation on the QuEST1 (NCT03493945) clinical trial at the European Society for Medical Oncology (ESMO), including the data and the next steps for this therapy. This trial produced an exceptional response rate of 55.6% in unselected, castration-resistant prostate cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).